Organoid: a small culture with selected tissue features
In one sentence
An organoid is a three-dimensional cell culture that self-organizes to reproduce selected structural or functional features of a tissue.
The intuition
Think of a small workshop that preserves some of a factory's layout. You can test what its workers do, but it lacks the factory's delivery network and surrounding town. An organoid similarly keeps useful tissue features without becoming a miniature patient. “Three-dimensional” describes the culture's arrangement, not how completely it represents the body.
How it works
Cells are grown under conditions that support organization, often within a gel-like matrix. The medium supplies nutrients and signals. Researchers may begin with normal adult tissue, tumor tissue or stem cells. A patient-derived tumor organoid is one member of this broader family.
The starting material and growth conditions select which cells survive. Some cancer populations expand well; others disappear. Normal epithelial cells can also grow. Comparing identity and relevant molecular features with the source specimen helps establish what the culture contains.
Many conventional epithelial organoids lack the original immune and supporting-cell populations. Specialized methods can retain selected neighbors or add them in a co-culture, a culture containing more than one cell population. That capability must be demonstrated for the actual experiment. The word organoid alone does not establish immune competence.
A culture's matrix, size, oxygen supply and treatment duration can affect its response. Expansion and repeated transfer into fresh cultures, called passaging, can change its composition. Record those conditions alongside the result.
Why it matters in cancer
Organoids can provide material for repeated, controlled experiments on tumor biology and drug response. They can help test a proposed mechanism. They do not reproduce human drug absorption, organ toxicity or every site of disease.
Worked example
A fictional tumor organoid contains verified malignant epithelial cells but no detectable T cells. It can support a direct tumor-cell drug experiment. It cannot answer whether a checkpoint-blocking antibody releases a useful T-cell response. Adding matched immune cells would create a new experiment whose composition and controls need checking.
Common confusions
- A rounded spheroid, an aggregate of cells, is not automatically an organoid with tissue-like organization. Terminology varies; inspect the method.
- A patient's cells do not make every culture component patient-matched.
- A successful culture need not contain every original cancer population.
- A viability change is not automatically tumor-cell killing or clinical benefit.
How it is measured
| Assay-card field | What to retain |
|---|---|
| Input and tissue cost | Viable starting material under the method's protocol; derivation and experiments consume material |
| Identity and composition | Evidence of malignancy, retained populations, matrix, medium and passage |
| Output | The chosen growth, death, molecular or interaction readout, with its units |
| Controls and thresholds | Defined separately for the experiment; no universal organoid-response cutoff |
| Validation | Model characterization and intended-use evidence, rather than the culture label alone |
Related concepts
Sources and scope
Source check: October 9, 2026. General model teaching; expert and learner review remain pending.
- Sachs et al., 2018: primary breast-cancer organoid biobank.
- Neal et al., 2018: selected organoid systems retaining tumor immune components.
- Dijkstra et al., 2018: matched organoid–lymphocyte experiments in colorectal and lung cancers — laboratory tumor recognition does not establish clinical utility in another setting.